Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. My name is Stefan and I'll be your conference operator today. At this time, I'd like to welcome you to the Chimera Therapeutics first quarter 2026 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there'll be a question and answer session. If you would like to ask a question during this time, and if you've joined via the webinar, please use the raised hand icon, which can be found at the bottom of your webinar application. If you've joined by phone, please dial star nine on your keypad to raise your hand. At this time, I'd like to turn the call over to Justine Konigsberg, Vice President of Investor Relations. Good morning and welcome to Chimera Therapeutics quarterly update conference call. Joining me today are Nello Mainalfi, our founder, president, chief executive officer, Jared Golub, our chief medical officer, and Bruce Jacobs, our chief financial officer. Following our prepared remarks, we will open the call for questions from our covering analysts. Please use the raise hand icon to indicate you'd like to ask a question, and we kindly ask that you limit your question to one so we can accommodate everyone. But before we begin, I would like to remind you that today's discussion will include forward-looking statements subject to risks and uncertainties described in our most recent Form 10-Q filed with the SEC, Please note any forward-looking statements speak only as of today's date, and we undertake no obligation to update them. With that, I will now turn the call over to Nello. Thanks, Justine, and thanks, everyone, for joining us this morning. Next week marks the 10-year anniversary of Chimera's founding, and it represents more than just a milestone. We have stepped into a new chapte...